Dean Falb,Jonathan W. Kotula,Vincent M. Isabella,Paul F. Miller,Alex Tucker,Yves Millet,Adam B. Fisher
申请号：
US16069199
公开号：
US20190282628A1
申请日:
2017.01.11
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells that comprise an amino acid catabolism enzyme for the treatment of diseases and disorders associated with amino acid metabolism, including cancer, in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with amino acid metabolism, such as cancer.
